PF-04856884

DB17550InvestigationalProtein Based Therapies

PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal...

Mechanism: Pharmacologically active on Angiopoietin-2
Curator reviewed
Code names: PF-04856884

Resolves to

Compound

UNII78LXD26OX3

Targets

O15123ANGPT2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-04856884, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account